Given their heterogeneity [58], therapeutic agents could be targeted solely to reactive retinal microglial cells [59], such as IL-34-dependent IPL-resident ones [60] or FGF-2-releasing retinopathy-promoting ones [61]. Here, FGF2 is linked to retinal disorder.